Stryker Corporation $SYK Shares Sold by Nisa Investment Advisors LLC

Nisa Investment Advisors LLC decreased its position in Stryker Corporation (NYSE:SYK) by 0.1% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 102,299 shares of the medical technology company’s stock after selling 126 shares during the quarter. Nisa Investment Advisors LLC’s holdings in Stryker were worth $40,558,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of SYK. Nuveen LLC purchased a new stake in shares of Stryker during the 1st quarter worth about $558,075,000. Price T Rowe Associates Inc. MD grew its position in Stryker by 9.2% in the first quarter. Price T Rowe Associates Inc. MD now owns 12,131,218 shares of the medical technology company’s stock worth $4,515,847,000 after acquiring an additional 1,021,496 shares in the last quarter. Alliancebernstein L.P. increased its stake in shares of Stryker by 66.7% during the 1st quarter. Alliancebernstein L.P. now owns 1,373,142 shares of the medical technology company’s stock worth $511,152,000 after purchasing an additional 549,643 shares during the last quarter. Vanguard Group Inc. raised its holdings in shares of Stryker by 1.1% during the 1st quarter. Vanguard Group Inc. now owns 33,059,964 shares of the medical technology company’s stock valued at $12,306,572,000 after purchasing an additional 361,136 shares in the last quarter. Finally, Goldman Sachs Group Inc. lifted its stake in shares of Stryker by 13.1% in the 1st quarter. Goldman Sachs Group Inc. now owns 2,252,895 shares of the medical technology company’s stock valued at $838,640,000 after purchasing an additional 261,058 shares during the last quarter. 77.09% of the stock is currently owned by institutional investors.

Stryker Price Performance

SYK stock opened at $381.86 on Friday. The company’s 50-day moving average price is $379.84 and its two-hundred day moving average price is $380.03. The company has a quick ratio of 1.06, a current ratio of 1.78 and a debt-to-equity ratio of 0.70. Stryker Corporation has a 12 month low of $329.16 and a 12 month high of $406.19. The firm has a market cap of $145.99 billion, a P/E ratio of 50.58, a P/E/G ratio of 2.75 and a beta of 0.94.

Stryker (NYSE:SYK) last announced its quarterly earnings results on Thursday, July 31st. The medical technology company reported $3.13 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.07 by $0.06. Stryker had a net margin of 12.25% and a return on equity of 23.94%. The firm had revenue of $6.02 billion during the quarter, compared to analysts’ expectations of $5.92 billion. During the same period in the prior year, the company posted $2.81 EPS. The company’s revenue was up 11.1% on a year-over-year basis. Stryker has set its FY 2025 guidance at 13.400-13.600 EPS. On average, analysts anticipate that Stryker Corporation will post 13.47 earnings per share for the current fiscal year.

Stryker Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Tuesday, September 30th will be paid a $0.84 dividend. The ex-dividend date is Tuesday, September 30th. This represents a $3.36 annualized dividend and a yield of 0.9%. Stryker’s dividend payout ratio (DPR) is 44.50%.

Insider Activity at Stryker

In other Stryker news, insider Viju Menon sold 500 shares of the business’s stock in a transaction dated Monday, August 25th. The shares were sold at an average price of $390.61, for a total value of $195,305.00. Following the transaction, the insider owned 12,511 shares in the company, valued at approximately $4,886,921.71. The trade was a 3.84% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Ronda E. Stryker sold 200,000 shares of the company’s stock in a transaction dated Wednesday, August 6th. The shares were sold at an average price of $376.45, for a total transaction of $75,290,000.00. Following the transaction, the director directly owned 3,222,108 shares of the company’s stock, valued at approximately $1,212,962,556.60. This trade represents a 5.84% decrease in their ownership of the stock. The disclosure for this sale can be found here. 5.90% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

SYK has been the subject of a number of recent research reports. Truist Financial cut their target price on Stryker from $415.00 to $407.00 and set a “hold” rating for the company in a research note on Wednesday, October 15th. Rothschild Redb upgraded shares of Stryker to a “hold” rating in a research note on Thursday, September 18th. Wells Fargo & Company lifted their target price on Stryker from $435.00 to $445.00 and gave the company an “overweight” rating in a research report on Friday, August 1st. BTIG Research raised their price target on Stryker from $407.00 to $408.00 and gave the company a “buy” rating in a research note on Monday, October 13th. Finally, Wall Street Zen upgraded Stryker from a “hold” rating to a “buy” rating in a research note on Saturday, October 18th. Fifteen research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $432.24.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.